BROMOPRIDE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H22BrN3O2.ClH
Molecular Weight	380.708
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC

InChI

InChIKey=SGQFXUUDHWNAIN-UHFFFAOYSA-N

InChI=1S/C14H22BrN3O2.ClH/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3;/h8-9H,4-7,16H2,1-3H3,(H,17,19);1H

HIDE SMILES / InChI

Molecular Formula	C14H22BrN3O2
Molecular Weight	344.247
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14871277 | http://www.medicinanet.com.br/bula/1015/bromopan.htm

Bromopride is a dopamine D2 receptor blocker. Bromopride exerts is a gastrointestinal prokinetic exploited clinically for the management of motor disorders of the upper gastrointestinal tract, including functional dyspepsia, gastric stasis of various origins and emesis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14871277 \| https://www.ncbi.nlm.nih.gov/pubmed/7823770	Antagonist 2778
cholinesterase activity 5 Target ID: GO:0004104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7823770	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dyspepsia 11 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28778685	Primary		Approved 8429	Bromopan Approved Use Principais: distúrbios digestivos psicossomáticos ad senectude e da estafa mental. Discinesias gastroduodenais e biliares. Colopatias espasmódicas. Enxaquecas e mal-estar de origem celíaca. Náuseas. Vômitos. Anorexia. Particulares: exames radiológicos do tubo digestivo. Preparação de explorações endoscópicas. Vômitos anestésicos. Soluços. Meteorismo abdominal pós-operatório. Manifestações digestivas após a aplicação de radioterapia.

PubMed

Title	Date	PubMed
Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass.	2005 May	15946465
Influence of bromopride in the prophylaxis of nausea associated with fluorescein angiography.	2007 Jan-Feb	17505728
Case-crossover study of Burkholderia cepacia complex bloodstream infection associated with contaminated intravenous bromopride.	2010 May	20205589

Patents

Sample Use Guides

In Vivo Use Guide

Capsules: 40-60 mg/day Oral solution: 40-60 mg/day (adults), 0.5-1 mg/kg (children)

Route of Administration: Oral

In Vitro Use Guide

Bromopride effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM. Bromopride can inhibit cholinesterase activity in all tissues studied,

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:56:16 UTC 2023` Edited by `admin` on `Fri Dec 15 17:56:16 UTC 2023`
Record UNII	B7C7WX94Z6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BROMOPRIDE HYDROCHLORIDE

Common Name

English

BROMOPRIDE HYDROCHLORIDE [MI]

Common Name

English

Bromopride hydrochloride [WHO-DD]

Common Name

English

BENZAMIDE, 4-AMINO-5-BROMO-N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-, HYDROCHLORIDE (1:1)

Systematic Name

English

Code System Code Type Description

SMS_ID

100000089001